# Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

> **NCT00460746** · PHASE3 · COMPLETED · sponsor: **Tibotec, Inc** · enrollment: 10 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** TMC125, Darunavir; Ritonavir

## Key facts

- **NCT ID:** NCT00460746
- **Lead sponsor:** Tibotec, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2013-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00460746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00460746, "Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00460746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*